Compare Boston Scientific Corporation (BSX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Boston Scientific Corporation trades at $43.5 (market cap $66.37B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.89. The key difference: YieldMax Magnificent 7 Fund of Option Income ETFs is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | YMAG | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $15.98 |
52-Week Low | $42.63 | $11.00 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
YMAG trades at $11.70, down 0.93% on the day, with technical indicators showing a neutral overall signal. The ETF has demonstrated consistent weekly dividend distributions throughout 2026, with payouts ranging from $0.07 to $0.40 per share. Recent news highlights YMAG's strategy of bundling Magnificent Seven exposure through option income ETFs, though some analysts express concerns about NAV decay and limited upside potential.
The outlook for YMAG hinges on its ability to generate sustainable option income while managing the trade-off between yield and capital appreciation. Key risks include high expense ratios, underperformance during strong bull markets, and dependence on volatility premiums. Institutional interest appears mixed, with the fund's appeal concentrated among income-focused investors seeking Magnificent Seven exposure with enhanced yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
